跳到正文
研踪PaperTrail

YOUR RESEARCH, IN SIGHT

让下一篇重要论文,不再错过。

覆盖计算机全学科,以 AI 为快捷入口。关注方向、作者和关键词,把发现变成持续的研究积累。

部分采集异常
正在读取账号与研究记录…

全站更新概况

+6109新增论文
+5222其中 AI 相关
+108已有论文修订
+122新增 AI 导读

arXiv 最近完成扫描:2026-11-05 07:04 · 全站最近入库:2026-11-05 06:17各信源进度 →

统计口径与数据新鲜度

统计 2026-11-04 07:04 — 2026-11-05 07:04(北京时间) · 点击数字查看对应简报;AI 相关包含在新增论文内。

最近完成检查:2026-11-05 07:04最近发现新增版本:2026-11-05 06:17库内论文最新更新时间:2026-11-04 08:00

每分钟刷新已保存的数据。空检查不代表采集异常;新收录可能包含历史论文。AI 导读按新增版本计数。

14,786 已收录论文12,897 AI 相关3,089 有修订112 HF 社区发现

浏览论文库

时间范围跟随排序:版本更新、本站收录或首次发表。最新收录可能包含历史论文。部分信源异常,查看状态 →

找到 1 篇论文 · 按版本更新时间排序上轮扫描起点 2026-11-05 07:02(北京时间)
新论文 · v1arXiv:2611.01730

Deep Learning for Cervical Cytology Screening: Methods, Algorithms, Challenges and Prospects

Jiang Yangbo, Zheng Nenggan

Cervical cancer remains a leading cause of cancer death among women, with more than 90\% of deaths occurring in low- and middle-income countries, where cytology screening is constrained by a shortage of trained cytopathologists. Deep learning has made automated cytology screening increasingly feasible, but the literature is fragmented across cell, patch and whole-slide-image scales, task formulations and supervision regimes, hindering comparison and clinical translation. This Review synthesizes the deep learning literature for cervical cytology screening, organizing the field along three axes---data scale, functional task and supervision---and distinguishing two clinical roadmaps: whole-slide-image confidence aggregation and cell-level detection with Bethesda classification. We examine 16 publicly available or publicly documented cytology datasets alongside the CAISHI histopathology dataset, compare quantitative performance while exposing incomparable metrics and data leakage, and assess commercial systems, regulatory status, HPV-era screening pathways and low-resource deployment. Single-cell accuracy on Herlev and SIPaKMeD has plateaued, but this reflects benchmark saturation rather than clinical readiness; prospective and randomized evidence is emerging but remains limited. We consolidate the evidence into five challenge areas---data and benchmarks, architecture and label-efficient learning, trustworthy AI, clinical translation and health economics, and evaluation and reproducibility---and provide an evidence-to-agenda map and a deployment decision matrix. Progress now depends on multi-center benchmarks, externally validated label-efficient methods, calibrated and fair predictions, and pragmatic clinical trials rather than further gains on saturated single-cell benchmarks.

尚无 AI 解读,展示原文摘要

cs.CV
arXiv ↗PDF ↗